Laura Nsangi

Enthusiastic clinical researcher coordinator, with over 5 years' experience in the conduct and management of ground breaking clinical trials including protocol development and implementation in accordance with ethical standards, team supervision and regulatory submission. Hardworking with excellent organization, leadership and management skills. Goal oriented, very analytical, inquisitive and readily take on new challenges.

Currently in the final year of MPH, particularly interested in pursuing a research career and hope to better equip myself with the knowledge and skills needed to make a difference through participating and conducting more quality research, with particular interest in the area of infectious diseases, where the biggest burden lies. For the past 2 years, I have coordinated trials among HIV infected participants with cryptococcal and TB meningitis and picked interest in the cryptococcal meningitis cohorts and particularly the neurocognitive outcomes in this population.

Publications:

- Implementation of accelerated research: Strategies for implementation as applied in a phase I Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines clinical trial in Uganda (EBOVAC I). Glob Health Action

. 2020 Dec 31;13(1):1829829. doi: 10.1080/16549716.2020.1829829.

- A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. AIDS 2020 34:1425-1428

- A journey of Hope: Giving Research Participants a voice to share their experiences and improve community engagement around advanced HIV disease in Uganda. AAS Open Research

Research Experience:

- AMBITION-cm (Study Coordinator): July 2019 to date

High dose Ambisome on a fluconazole backbone for cryptococcal meningitis induction therapy in Sub-Saharan Africa: A phase II Randomized Controlled Non-Inferiority Trial

- COAST (Study Coordinator): July 2019 to date

Improved Diagnostics and Neurological outcomes in HIV associated meningitis.

- GWAS (Study Coordinator): September 2020 to date

Collection of control DNA samples for the AMBITION-cm host susceptibility to cryptococcal infection sub-study (a genome wide association study). A sub-study of the AMBITION-cm Trial

- RIFT Valley Fever Virus Survivor's Study (Sub Investigator): September 2018 - July 2019

A study investigating cellular and humoral immune responses among recently infected rift valley fever survivors.

- Ebola Phase II Vaccine Trial (Study Medical Officer): November 2015 - January 2019

of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola MVA-BN-Filo and Ad26.ZEBOV in Healthy Adults, Including Elderly Subjects, HIV Infected Subjects and Healthy Children in Three Age Strata in Africa.

- Ebola Phase I Vaccine Trial (Study Medical Officer): July 2015 - February 2017

Randomized, Observer Blind Placebo Controlled Phase II Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens using MVA-BN-Filo and Ad.26ZEBOV Administered in different Sequences and Schedules in Healthy Adults.

Presentations:

September 2021: AMBITION Study Investigators' Meeting

Infectious Diseases Institute, Kampala, Uganda

Leadership and Management in Health

Professor David Meya, MD, MMed, PhD

Infectious Diseases Institute

P.O. Box 22418

Mulago Hospital Complex Kampala, Uganda

Phone: +256 772 543 730

Email: david.meya@gmail.com

Professor David R Boulware, MD, MPH,CTropMed

University of Minnesota

2001 6th street SE, MTRF 3-222

Minneapolis, MN 55455 USA

Phone: +1 612 626 9546

Email: boulw001@umn.edu

Dr Freddie Kibengo, MD, Mmed, MPH

MRC/UVRI and LSHTM Uganda Research Unit

P.O. Box 49, Entebbe Uganda

Phone +256 772 435 251

Email: Freddie.Kibengo@mrcuganda.org